

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	09441140	
		Filing Date	1999-11-16	
		First Named Inventor	Beka SOLOMON	
		Art Unit	1649	
		Examiner Name	G. S. Emek K. Ballard	
		Attorney Docket Number	SOLOMON1R	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
			<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09441140
Filing Date	1999-11-16
First Named Inventor	Beka SOLOMON
Art Unit	1649
Examiner Name	O. S. Enrich K. Ballard
Attorney Docket Number	SOLOMON1R

1	Bacska et al., "Imaging of Amyloid-β Deposits in Brains of Living Mice Permits Direct Observation of Clearance of Plaques with Immunotherapy", Nature Medicine, 7:369-372 (2001)	<input type="checkbox"/>
2	Bard et al., "Epitope and Isotype Specificities of Antibodies to β-Amyloid Peptide for Protection Against Alzheimer's Disease-like Neuropathology", Proc. Natl. Acad. Sci. USA, 100:2023-2028 (2003)	<input type="checkbox"/>
3	Bard et al., "Peripherally Administered Antibodies Against Amyloid β-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease", Nature Medicine, 6:916-919 (2000)	<input type="checkbox"/>
4	Bickel et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against (jA4 Protein: A Potential Probe for Alzheimer's Disease", Bioconjugate Chem., 5:119-125 (1994)	<input type="checkbox"/>
5	DeMattos et al., "Peripheral Anti-AB Antibody Alters CNS and Plasma AB Clearance and Decreases Brain AB Burden in a Mouse Model of Alzheimer's Disease", Proc. Natl. Acad. Sci. USA, 98:88-50-8855 (2001)	<input type="checkbox"/>
6	FRASER et al, "Morphology and antibody recognition of synthetic beta-amyloid peptides," J Neurosci Res 28 (4):474-485 (1991)	<input type="checkbox"/>
7	Frenkel et al., "High Affinity Binding of Monoclonal Antibodies to the Sequential Epitope EFRH of β-Amyloid Peptide is Essential for Modulation of Fibrillar Aggregation", Journal of Neuroimmunology, 95:136-142 (1999)	<input type="checkbox"/>
8	Johnson-Wood et al., "Amyloid Precursor Protein Processing and Ab42 Deposition in a Transgenic Mouse Model of Alzheimer Disease", Proc. Natl. Acad. Sci. USA, 94:1550-1555 (1997)	<input type="checkbox"/>
9	SIMPSON et al, "Autoantibodies to Alzheimer and normal brain structures from virus-transformed lymphocytes. J Neuroimmunol 13(1): 1-8 (1986)	<input type="checkbox"/>
10	Solomon et al., "Disaggregation of Alzheimer β-Amyloid by Site-Directed mAb", Proc. Natl. Acad. Sci. USA, 94:4109-4112 (1997)	<input type="checkbox"/>
11	Solomon et al., "The Amino Terminus of the β-Amyloid Peptide Contains an Essential Epitope for Maintaining its Solubility", in Progress in Alzheimer's and Parkinson's Diseases, Fisher et al., ed., Plenum Press, New York, 205-211 (1998)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09441140
Filing Date	1999-11-16
First Named Inventor	Beka SOLOMON
Art Unit	1649
Examiner Name	O.O. Embr K. Ballard
Attorney Docket Number	SOLOMON1R

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Kimberly Ballard/	Date Considered	02/03/2009
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.